SCHEMBL29688602

SCHEMBL29688602

COc1ccc(C2COc3cc(O)cc(O)c3C2=O)c(O)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 5/20 0.55
KMT2A Q03164 3/20 0.51
MAPT P10636 3/20 0.51
POLB P06746 2/20 0.51
MEN1 O00255 2/20 0.51
THRB P10828 1/20 0.51
HTT P42858 1/20 0.51
BLM P54132 1/20 0.51
TYR P14679 1/20 0.51
ALOX15 P16050 2/20 0.50
ALOX12 P18054 2/20 0.50
CBS P35520 1/20 0.49
CYP1A1 P04798 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP1B1 Q16678 1/20 0.47
RECQL P46063 2/20 0.46
CYP19A1 P11511 3/20 0.45
CYP3A4 P08684 2/20 0.43
HPGD P15428 2/20 0.43
USP2 O75604 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29737519 0.87 TDP1 (0.53) PTPN1KMT2AMEN1TYRALOX12
Dihydrobiochanin A SCHEMBL30217535 0.86 ALOX12 (0.67) PTPN1KMT2AMAPTPOLBMEN1
SCHEMBL30561814 0.84 PTPN1 (0.60) PTPN1KMT2AMAPTMEN1TYR
SCHEMBL213646 0.84 PTPN1 (0.60) PTPN1KMT2AMAPTMEN1TYR
SCHEMBL572085 0.81 PTPN1 (0.67) PTPN1KMT2AMAPTPOLBMEN1
SCHEMBL31238344 0.81 PTPN1 (0.56) PTPN1KMT2AMAPTPOLBMEN1
Cajanol SCHEMBL571648 0.81 PTPN1 (0.53) PTPN1KMT2AMAPTMEN1ALOX15
SCHEMBL28824122 0.81 TYR (0.54) PTPN1KMT2AMAPTPOLBMEN1
SCHEMBL9993958 0.80 PTPN1 (0.50) PTPN1KMT2AMAPTPOLBMEN1
SCHEMBL1842904 0.77 PTPN1 (0.71) PTPN1KMT2AMAPTPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023219526-A1 MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT PROKIN MILAN (RS) 2023-11-16 WO claimed
US-12577526-B2 Massively parallel on-chip construction of synthetic microbial communities THE BROAD INSTITUTE, INC. (US) 2026-03-17 US disclosed
US-20250376656-A1 MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2025-12-11 US disclosed
WO-2023219526-A1 MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT PROKIN MILAN (RS) 2023-11-16 WO disclosed
US-20220228190-A1 MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2022-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577526-B2 Massively parallel on-chip construction of synthetic microbial communities STUB1, SAMM50, CD14 PTPN1 85/4885KMT2A 4140/4885MAPT 1771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.